Fluorouracil News and Research

RSS

Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.

Chemotherapy-induced anemia increases risk of local breast cancer recurrence

Patients with breast cancer who developed anemia during chemotherapy had nearly three times the risk of local recurrence as those who did not, according to a study published in the April 1 issue of Clinical Cancer Research¸ a journal of the American Association for Cancer Research.

2 Apr 2008

Postoperative chemotherapy does not improve survival in gastric cancer patients

The use of combination chemotherapy following surgery did not improve survival in patients with gastric cancer, according to a randomized clinical trial published online March 11 in the Journal of the National Cancer Institute .

12 Mar 2008

Chemotherapy with chemoradiation for pancreatic cancer has small survival benefit

The addition of the drug gemcitabine with chemoradiation for the treatment of patients who had surgery for pancreatic cancer was associated with a survival benefit, although this improvement was not statistically significant, according to a study in the March 5 issue of JAMA.

6 Mar 2008

Study may aid pancreatic cancer patients' response to chemo drugs

Pancreatic cancer patients face the worst survival rates compared to all other forms of human cancer as the disease is nearly impossible to diagnose at an early stage when successful treatments might be possible.

1 Nov 2007

Combination targets offer new hope in fight against cancer

While some targeted therapies - drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells - work well by themselves, increasingly researchers are finding that they work better when teamed with other targeted and conventional therapies.

24 Oct 2007

Cancer drug Taxotere given the green light to treat head and neck cancer

Following promising results in a phase III trial, the drug Taxotere has been given the green light for use in people with head and neck cancer.

2 Oct 2007

Taxotere (docetaxel) granted FDA approval to treat locally advanced head and neck cancer prior to chemo and surgery

Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) has approved Taxotere (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil for induction therapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN) before patients undergo chemoradiotherapy and surgery.

2 Oct 2007

PET scans accurately detect a breast tumor's response to chemotherapy

Researchers in Australia have shown that positron emission tomography (PET) that uses a radioactive sugar molecule is more useful than mammography and ultrasound in predicting a breast tumour's response to chemotherapy and, therefore, the patient's ultimate likelihood of survival.

26 Sep 2007

Phase II study of TroVax vaccine in patients with metastatic colorectal cancer

A therapeutic cancer vaccine has shown effectiveness when given alongside chemotherapy to patients with metastatic colorectal cancer in a phase II trial, according to researchers at Oxford BioMedica (UK) Ltd.

2 Aug 2007

Study of therapeutic vaccine shows promise for metastatic colorectal cancer

1 Aug 2007

Sequential and combination chemotherapy equally effective in treating advanced colorectal cancer

Many patients with incurable advanced colorectal cancer could be offered a more gentle treatment strategy starting with a single chemotherapy drug, as an alternative to current standard initial combination chemotherapy, without compromising their survival.

16 Jul 2007

Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

The number of lymph nodes that contain evidence of cancer is the best predictor of the effectiveness of adding chemotherapy and radiation to a treatment plan prior to surgery in individuals with oesophageal cancer, according to a study published last month in the Annals of Surgery.

16 Jul 2007

Fat kills cancer!

Researchers in Slovakia have been able to derive mesenchymal stem cells from human adipose, or fat, tissue and engineer them into "suicide genes" that seek out and destroy tumors like tiny homing missiles.

3 Jul 2007

Physiological differences between men and women impact colorectal cancer progression

Physiological differences between men and women may contribute to differential tumor development and progression in colon cancer patients, a study led by researchers at the University of Southern California (USC) suggests.

5 Jun 2007

New drugs to fight colon and breast cancer

A study on epithelial cell lines has allowed for the development of six new drugs to fight colon and breast cancer more effectively than other currently used drugs.

3 Jun 2007

Cancer Research Technology licenses therapeutic antibodies to Peptech

Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announces it has licensed rights to a panel of cancer therapeutic antibodies to Peptech Limited.

2 May 2007

Viventia Biotech announces results of Proxinium antibody in combinaton with chemotherapy and radiation

Viventia Biotech has announced results of in vitro cytotoxicity and in vivo pharmacokinetic studies conducted to evaluate the potential for combining its phase III anti-cancer antibody therapeutic, Proxinium, with first-line standard of care therapy for squamous cell carcinoma of the head & neck (SCCHN).

19 Apr 2007

ADVENTRX announces positive data from multidrug therapy with cofactor

ADVENTRX Pharmaceuticals has announced positive results from preclinical studies using a multidrug treatment regimen including ANX-510 (CoFactor) at the American Association for Cancer Research (AACR) Annual Meeting.

19 Apr 2007

New treatment option gives hope to victims of head and neck cancers

More than 640,000 people worldwide are diagnosed with head and neck cancer each year, and more than 350,000 die from the disease annually.

19 Oct 2006

FDA approves Taxotere for head and neck cancers

The Food and Drug Administration (FDA) today approved Taxotere (docetaxel) Injection Concentrate for use in combination with cisplatin and fluorouracil prior to radiotherapy for the treatment of patients with inoperable, locally advanced squamous cell carcinoma of the head and neck (SCCHN).

18 Oct 2006